Psych Congress

Even mild cases tied to reduced quality of life and high medical costs, survey showed

Analysis shows that many patients are treated for symptoms of the disorder before diagnosis

Potential add-on therapy also improved most individual depressive symptoms on MADRS

Even at 10 mg, the sleep aid resulted in few abnormal dreams or nightmares

Not much data to support efficacy or safety "as a surrogate hypnotic medication," researcher says

But atypical antipsychotic disappoints in borderline personality disorder

Xanomeline-trospium has potential to be first-in-class therapy for schizophrenia if approved

Pooled data from randomized trials showed better scores on the PHQ-9 as well

Even patients with history of depression had better sleep outcomes

Improvement with 50-mg zuranolone seen by day 3

Early use linked to fewer inpatient stays and ER visits, study finds

Phase III RISE study found benefit with both once-monthly and bimonthly dose

Survey study shows no major changes in prescription trends in 2020

Real-world study of fremanezumab found that patients were able to reduce antidepressant use